Ask the Expert: Multiparameter
Flow Cytometry in Measurable Residual Disease
Assessment of measurable residual disease (MRD) in acute myeloid leukemia (AML) is an important prognostic indicator, particularly since approximately 50% of patients with acute myeloid leukemia who achieve morphological complete remission (CR) relapse. Given this high rate of relapse, it is evident that the current definition of morphological CR does not adequately predict outcomes in a significant proportion of AML patients.
Multiparameter flow cytometry is an important diagnostic tool used in the assessment of MRD, but its use is challenging in the clinical setting, not only due to the heterogeneity of the disease and the complexity of the testing methodology, but also due to its lack of standardization. In response, the European LeukemiaNet (ELN) Working Party published a consensus document in an effort to provide guidelines on the use of MRD assessment in clinical practice, and multiparameter flow cytometry was identified as an integral part of MRD assessment in AML.
Tune in and learn how standardization—and harmonization—is critical to integrating multiparameter flow cytometry assessment for MRD into routine clinical care in AML patients.
Register HERE
The Expert:
Dr. Michelle J. McNamara
Director of Medical & Scientific Affairs
BD Life Sciences - Biosciences
Dr. Michelle J. McNamara received her MD training at Meharry Medical College and completed residency training in Anatomic and Clinical Pathology and Fellowship training in Hematopathology at the University of California Davis. Her years of private clinical practice in both the reference laboratory and the hospital settings sharpened her skills in hematopathology with special emphasis in flow cytometry having served as the Director of the Flow Cytometry Laboratory for the Southeast region of Quest Diagnostics™. As an ASCP-certified Medical Technologist, she has an in-depth knowledge of the clinical laboratory, its workflow, instruments, and unique needs. Her current research interests include the tumor microenvironment and its role in immune checkpoint inhibitor therapy and circulating tumor cells in the peripheral circulation and body fluids.